GEN Exclusives

More »

GEN News Highlights

More »
Dec 27, 2012

Parexel Takes Over Liquent

  • Parexel International acquired all of the outstanding equity securities of Liquent, a company that provides software solutions for regulatory submissions and product registration management, as well as a range of complementary business process outsourcing capabilities. The purchase price was approximately $72 million.

    “The acquisition of Liquent further strengthens our regulatory capabilities by adding a robust information technology platform,” explained Josef von Rickenbach, chairman and CEO of Parexel. “Through Liquent’s flagship software platform, InSight®, our clients will have access to comprehensive regulatory agency submission planning, viewing, tracking, publishing, and registration management throughout the entire lifecycle of a medicinal entity. We expect the acquisition will also benefit the Parexel consulting and medical communications services business, where we will be able to leverage Liquent’s expertise in regulatory information management outsourcing through its Liquent Direct® solutions.”

    Earlier this month, Perceptive Informatics, an eClinical solutions provider and a Parexel subsidiary, opened a customer care office in Shanghai to service biopharmaceutical researchers in China and Taiwan. The customer care office staff will initially be responsible for supporting clinical studies using ClinPhone® RTSM (randomization and trial supply management) and Datalabs® EDC software and services. It will serve as the first point of contact for clinical site staff, clinical research associates, and sponsors.


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...

Unable to get Jobs Listings.

More »

GEN Poll

More » Poll Results »

Biosimilars

Compared to the original biologics, do you think biosimilars run the risks of being less effective and causing more side effects?